What is genetic testing for cancer?

This article gives a good summary of the use of genetic tests to indicate your risk of developing certain cancers, as well as the down sides of genetic testing. Genetic tests can determine whether you are at risk of developing cancer by finding mutations in a person’s genes. The risk of developing cancer increases if […]

read more

ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Cristina Suarez from the Hospital Universitari Vall D’Hebron and Vall D’Hebron Institute of Oncology in Barcelona, Spain presented an update of the clinical data from the phase 2 study of oral HIF-2a MK-6482 in Von Hippel-Lindau disease-associated cancers. Von Hippel-Lindau disease is a […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

VHL disease and HIF-2alpha inhibitor

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, USA speaks about the use of  hypoxia-inducible factor (HIF) 2alpha inhibitor for the treatment of renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease. Firstly, Dr Jonasch describes how HIF-2alpha combines with HIF-1beta to act as a transcription factor […]

read more

Pazopanib for the treatment of von Hippel-Lindau disease

The results from a phase II clinical trial, which demonstrates the potential for first-line treatment with pazopanib as an alternative to surgery in patients with von Hippel-Lindau disease, were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this week. Thirty-two patients with von Hippel-Lindau disease (VHL) confirmed by genetic testing, […]

read more
Showing all 5 results